ReviewBritish journal of clinical pharmacology2016
Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Review in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Repurposing chlorpromazine to treat COVID-19: The reCoVery study.L'Encephale · 2020Trial
- A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen.International journal of molecular sciences · 2025Review
- Interplay of Neuroinflammation and Epilepsy in Glioblastoma Multiforme: Mechanisms and Therapeutic Implications.Journal of molecular neuroscience : MN · 2025Review
- The Impact of the Antipsychotic Medication Chlorpromazine on Cytotoxicity through CaNeurotoxicity research · 2022Article
- Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.British journal of clinical pharmacology · 2022Review
- Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.Biomolecules · 2021Review
- Propranolol Inhibits the Proliferation of Human Glioblastoma Cell Lines through Notch1 and Hes1 Signaling System.Journal of Korean Neurosurgical Society · 2021Article
- Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-DPharmacology research & perspectives · 2021Article
- Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.International journal of antimicrobial agents · 2021Article
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.PloS one · 2021Article
- Drug vector representation: a tool for drug similarity analysis.Molecular genetics and genomics : MGG · 2020Article
- Article
- New drugs are not enough‑drug repositioning in oncology: An update.International journal of oncology · 2020Review
- Review
- The interplay among psychological distress, the immune system, and brain tumor patient outcomes.Current opinion in behavioral sciences · 2019Article
- Article
- DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance.Genetics and molecular biology · 2019Article
- Receptor-Targeted Glial Brain Tumor Therapies.International journal of molecular sciences · 2018Review
- A novel computational approach for drug repurposing using systems biology.Bioinformatics (Oxford, England) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is a brain neoplasm with limited 5-year survival rates. Developments of new treatment regimens that improve patient survival in patients with glioblastoma are needed. It is likely that a number of existing drugs used in other conditions have potential anticancer effects that offer significant survival benefit to glioblastoma patients. Identification of such drugs could provide a novel treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.